{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T07:12:10Z","timestamp":1783408330249,"version":"3.54.6"},"reference-count":42,"publisher":"SAGE Publications","issue":"s2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JND"],"published-print":{"date-parts":[[2021,11,30]]},"abstract":"<jats:p>Background: AAV-based gene therapy is an attractive approach to treat Duchenne muscular dystrophy (DMD) patients. Although the long-term consequences of a gene therapy approach for DMD are unknown, there is evidence in both DMD patients and animal models that dystrophin replacement by gene therapy leads to an anti-dystrophin immune response that is likely to limit the long-term use of these therapeutic strategies. Objective: Our objective is to test whether the anti-dystrophin immune response is affected by immunomodulatory drugs in mdx mice after rAAV gene therapy. Methods: mdx mice were treated with rAAV microdystrophin alone or in combination with immunomodulatory drugs. Dystrophin expression in skeletal muscle was assessed by mass spectrometry. Immune responses were assessed by immunophenotyping, western blot for anti-dystrophin antibodies and flow cytometry assays for antigen-specific T-cell cytokine expression. The impact on muscle was measured by grip strength assessment, in vivo torque, optical imaging for inflammation and H&amp;E staining of sections to assess muscle damage. Results: We found that AAV-9-microdystrophin gene therapy induced expression of microdystrophin, anti-dystrophin antibodies, and T-cell cytokine responses. Immunomodulatory treatments, rituximab and VBP6 completely abrogated the anti-dystrophin antibody response. Prednisolone, CTLA4-Ig, and eplerenone showed variable efficacy in blocking the anti-dystrophin immune response. In contrast, none of the drugs completely abrogated the antigen specific IFN-\u03b3 response. AAV-microdystrophin treatment significantly reduced inflammation in both forelimbs and hindlimbs, and the addition of prednisolone and VBP6 further reduced muscle inflammation. Treatment with immunomodulatory drugs, except eplerenone, enhanced the beneficial effects of AAV-microdystrophin therapy in terms of force generation. Conclusions: Our data suggest that AAV-microdystrophin treatment results in anti-dystrophin antibody and T-cell responses, and immunomodulatory treatments have variable efficacy on these responses.<\/jats:p>","DOI":"10.3233\/jnd-210706","type":"journal-article","created":{"date-parts":[[2021,9,24]],"date-time":"2021-09-24T12:55:36Z","timestamp":1632488136000},"page":"S325-S340","source":"Crossref","is-referenced-by-count":16,"title":["The Effect of Immunomodulatory Treatments on Anti-Dystrophin Immune Response After AAV Gene Therapy in Dystrophin Deficient mdx Mice"],"prefix":"10.1177","volume":"8","author":[{"given":"Ning","family":"Li","sequence":"first","affiliation":[{"name":"School of Pharmacy and Pharmaceutical Sciences, Binghamton University, Binghamton, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna E.","family":"Parkes","sequence":"additional","affiliation":[{"name":"School of Pharmacy and Pharmaceutical Sciences, Binghamton University, Binghamton, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Spathis","sequence":"additional","affiliation":[{"name":"School of Pharmacy and Pharmaceutical Sciences, Binghamton University, Binghamton, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Morales","sequence":"additional","affiliation":[{"name":"School of Pharmacy and Pharmaceutical Sciences, Binghamton University, Binghamton, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Mcdonald","sequence":"additional","affiliation":[{"name":"School of Pharmacy and Pharmaceutical Sciences, Binghamton University, Binghamton, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan M.","family":"Kendra","sequence":"additional","affiliation":[{"name":"School of Pharmacy and Pharmaceutical Sciences, Binghamton University, Binghamton, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily M.","family":"Ott","sequence":"additional","affiliation":[{"name":"Department of Pathology and Neuroscience Research Center, Medical College of Wisconsin, Milwaukee, WI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristy J.","family":"Brown","sequence":"additional","affiliation":[{"name":"Solid Biosciences Inc, Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W.","family":"Lawlor","sequence":"additional","affiliation":[{"name":"Department of Pathology and Neuroscience Research Center, Medical College of Wisconsin, Milwaukee, WI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanneboyina","family":"Nagaraju","sequence":"additional","affiliation":[{"name":"School of Pharmacy and Pharmaceutical Sciences, Binghamton University, Binghamton, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"issue":"15","key":"10.3233\/JND-210706_ref1","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJMoa1000228","article-title":"Dystrophin immunity in Duchenne\u2019s muscular dystrophy","volume":"363","author":"Mendell","year":"2010","journal-title":"N Engl J Med"},{"issue":"3","key":"10.3233\/JND-210706_ref2","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1006\/mthe.2002.0675","article-title":"Immune response to full-length dystrophin delivered to Dmd muscle by a high-capacity adenoviral vector","volume":"6","author":"Gilchrist","year":"2002","journal-title":"Mol Ther [Internet]"},{"issue":"5","key":"10.3233\/JND-210706_ref3","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/nm0506-592b","article-title":"Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response","volume":"12","author":"Manno","year":"2006","journal-title":"Nat Med"},{"issue":"3","key":"10.3233\/JND-210706_ref4","doi-asserted-by":"crossref","first-page":"323","DOI":"10.2174\/1566523054065039","article-title":"Immune responses to adeno-associated virus vectors","volume":"5","author":"Zaiss","year":"2005","journal-title":"Curr Gene Ther"},{"issue":"1","key":"10.3233\/JND-210706_ref5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00705-003-0241-3","article-title":"Can genes transduced by adeno-associated virus vectors elicit or evade an immune response?","volume":"149","author":"Wang","year":"2004","journal-title":"Arch Virol"},{"issue":"23","key":"10.3233\/JND-210706_ref6","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1038\/sj.gt.3301829","article-title":"Adeno-associated virus vector-mediated gene transfer into dystrophin-deficient skeletal muscles evokes enhanced immune response against the transgene product","volume":"9","author":"Yuasa","year":"2002","journal-title":"Gene Ther"},{"issue":"13","key":"10.3233\/JND-210706_ref7","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1089\/10430340260201725","article-title":"Delivery of alpha- and beta-sarcoglycan by recombinant adeno-associated virus: Efficient rescue of muscle, but differential toxicity","volume":"13","author":"Dressman","year":"2002","journal-title":"Hum Gene Ther"},{"issue":"17","key":"10.3233\/JND-210706_ref8","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1038\/sj.gt.3301259","article-title":"Immune responses to dystropin: Implications for gene therapy of Duchenne muscular dystrophy","volume":"7","author":"Ferrer","year":"2000","journal-title":"Gene Ther"},{"issue":"2","key":"10.3233\/JND-210706_ref9","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0955-0674(99)80027-1","article-title":"Costimulatory regulation of T cell function","volume":"11","author":"Chambers","year":"1999","journal-title":"Curr Opin Cell Biol"},{"issue":"4","key":"10.3233\/JND-210706_ref10","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1517\/13543784.12.4.673","article-title":"The therapeutic potential of costimulatory blockade with CTLA4Ig in rheumatoid arthritis","volume":"12","author":"Emery","year":"2003","journal-title":"Expert Opin Investig Drugs"},{"issue":"47","key":"10.3233\/JND-210706_ref11","doi-asserted-by":"crossref","first-page":"7359","DOI":"10.1038\/sj.onc.1206939","article-title":"Rituximab (monoclonal anti-CD20 antibody): Mechanisms of action and resistance","volume":"22","author":"Smith","year":"2003","journal-title":"Oncogene"},{"issue":"8","key":"10.3233\/JND-210706_ref12","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1016\/j.bmc.2013.02.009","article-title":"VBP Preclinical characterization of a novel anti-inflammatory delta 9,11 steroid","volume":"21","author":"Reeves","year":"2013","journal-title":"Bioorg Med Chem"},{"issue":"4","key":"10.3233\/JND-210706_ref13","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/eurjhf\/hfp023","article-title":"Anti-inflammatory effects of eplerenone on viral myocarditis","volume":"11","author":"Xiao","year":"2009","journal-title":"Eur J Heart Fail"},{"issue":"9","key":"10.3233\/JND-210706_ref14","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1089\/hum.2013.092","article-title":"Anti-dystrophin T cell responses in Duchenne muscular dystrophy: Pevalence and a glucocorticoid treatment effect","volume":"24","author":"Flanigan","year":"2013","journal-title":"Hum Gene Ther"},{"key":"10.3233\/JND-210706_ref15","doi-asserted-by":"crossref","unstructured":"Baudy A , Sali A , Jordan S , Kesari A , Johnston H , Hoffman E , et al. Non-invasive optical imaging of muscle pathology in mdx mice using cathepsin caged near-infrared imaging. Mol imaging Biol. 2011;13(3).","DOI":"10.1007\/s11307-010-0376-z"},{"issue":"6","key":"10.3233\/JND-210706_ref16","first-page":"1927","article-title":"Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study","volume":"92","author":"Coiffier","year":"1998","journal-title":"Blood"},{"issue":"7","key":"10.3233\/JND-210706_ref17","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1161\/01.RES.0000244092.95152.86","article-title":"Novel effect of mineralocorticoid receptor antagonism to reduce proinflammatory cytokines and hypothalamic activation in rats with ischemia-induced heart failure","volume":"99","author":"Kang","year":"2006","journal-title":"Circ Res"},{"issue":"5","key":"10.3233\/JND-210706_ref18","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.ymthe.2017.02.019","article-title":"Progress toward Gene Therapy for Duchenne Muscular Dystrophy","volume":"25","author":"Chamberlain","year":"2017","journal-title":"Mol Ther"},{"key":"10.3233\/JND-210706_ref19","doi-asserted-by":"crossref","unstructured":"Kirchenbaum G , Hanson J , Roen D , Lehmann P . Detection of Antigen-Specific T Cell Lineages and Effector Functions Based on Secretory Signature. J Immunol Sci. 2019;3(2).","DOI":"10.29245\/2578-3009\/2019\/2.1168"},{"issue":"3","key":"10.3233\/JND-210706_ref20","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/path.5263","article-title":"Morpholino-induced exon skipping stimulates cell-mediated and humoral responses to dystrophin in mdx mice","volume":"248","author":"Vila","year":"2019","journal-title":"J Pathol"},{"issue":"10","key":"10.3233\/JND-210706_ref21","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1093\/hmg\/ddt656","article-title":"Role of toll-like receptors in the pathogenesis of dystrophin-deficient skeletal and heart muscle","volume":"23","author":"Henriques-Pons","year":"2014","journal-title":"Hum Mol Genet"},{"issue":"3","key":"10.3233\/JND-210706_ref22","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1046\/j.1365-2249.1998.00664.x","article-title":"A variety of cytokines and immunologically relevant surface molecules are expressed by normal human skeletal muscle cells under proinflammatory stimuli","volume":"113","author":"Nagaraju","year":"1998","journal-title":"Clin Exp Immunol"},{"issue":"2","key":"10.3233\/JND-210706_ref23","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1006\/clim.1999.4743","article-title":"Costimulatory markers in muscle of patients with idiopathic inflammatory myopathies and in cultured muscle cells","volume":"92","author":"Nagaraju","year":"1999","journal-title":"Clin Immunol"},{"issue":"6","key":"10.3233\/JND-210706_ref24","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1097\/01.bor.0000179947.58271.9a","article-title":"Role of major histocompatibility complex class I molecules in autoimmune myositis","volume":"17","author":"Nagaraju","year":"2005","journal-title":"Curr Opin Rheumatol"},{"key":"10.3233\/JND-210706_ref25","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1740-2557-3-2","article-title":"Endothelial cell activation and neovascularization are prominent in dermatomyositis","volume":"3","author":"Nagaraju","year":"2006","journal-title":"J Autoimmune Dis"},{"issue":"2","key":"10.3233\/JND-210706_ref26","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S0002-9440(10)65141-3","article-title":"Expression of the costimulatory molecule BB-1, the ligands CTLA-4 and CD28, and their mRNA in inflammatory myopathies","volume":"155","author":"Murata","year":"1999","journal-title":"Am J Pathol"},{"issue":"11","key":"10.3233\/JND-210706_ref27","doi-asserted-by":"crossref","first-page":"5943","DOI":"10.4049\/jimmunol.161.11.5943","article-title":"Human muscle cells express a functional costimulatory molecule distinct from B7.1 (CD80) and B7.2 (CD86) in vitro and in inflammatory lesions","volume":"161","author":"Behrens","year":"1998","journal-title":"J Immunol"},{"key":"10.3233\/JND-210706_ref28","doi-asserted-by":"crossref","unstructured":"Rosenberg AS , Puig M , Nagaraju K , Hoffman EP , Villalta SA , Rao VA , et al. Immune-mediated pathology in Duchenne muscular dystrophy. Sci Transl Med. 2015;7(299).","DOI":"10.1126\/scitranslmed.aaa7322"},{"issue":"2","key":"10.3233\/JND-210706_ref29","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1006\/clim.2000.4966","article-title":"Helper (CD4+) and cytotoxic (CD8+) T cells promote the pathology of dystrophin-deficient muscle","volume":"98","author":"Spencer","year":"2001","journal-title":"Clin Immunol"},{"issue":"11","key":"10.3233\/JND-210706_ref30","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1172\/JCI119464","article-title":"Myonuclear apoptosis in dystrophic mdx muscle occurs by perforin-mediated cytotoxicity","volume":"99","author":"Spencer","year":"1997","journal-title":"J Clin Invest"},{"issue":"5","key":"10.3233\/JND-210706_ref31","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1002\/mus.21211","article-title":"Preclinical drug trials in the mdx mouse: Assessment of reliable and sensitive outcome measures","volume":"39","author":"Spurney","year":"2009","journal-title":"Muscle Nerve"},{"issue":"1","key":"10.3233\/JND-210706_ref32","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1093\/hmg\/ddv460","article-title":"Effect of genetic background on the dystrophic phenotype in mdx mice","volume":"25","author":"Coley","year":"2016","journal-title":"Hum Mol Genet"},{"issue":"1","key":"10.3233\/JND-210706_ref33","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/mus.20646","article-title":"Weekly oral prednisolone improves survival and strength in male mdx mice","volume":"35","author":"Keeling","year":"2007","journal-title":"Muscle and Nerve"},{"issue":"1","key":"10.3233\/JND-210706_ref34","first-page":"1","article-title":"Muscular dystrophy in the mdx mouse is a severe myopathy compounded by hypotrophy, hypertrophy and hyperplasia","volume":"5","author":"Duddy","year":"2015","journal-title":"Skelet Muscle [Internet]"},{"issue":"1","key":"10.3233\/JND-210706_ref35","first-page":"9","article-title":"Old and new therapeutic developments in steroid treatment in Duchenne muscular dystrophy","volume":"31","author":"Angelini","year":"2012","journal-title":"Acta Myol"},{"key":"10.3233\/JND-210706_ref36","doi-asserted-by":"crossref","unstructured":"Sali A , Guerron A , Gordish-Dressman H , Spurney C , Iantorno M , Hoffman E , et al. Glucocorticoid-treated mice are an inappropriate positive control for long-term preclinical studies in the mdx mouse. PLoS One. 2012;7(4).","DOI":"10.1371\/journal.pone.0034204"},{"issue":"10","key":"10.3233\/JND-210706_ref37","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1002\/emmm.201302621","article-title":"VBP15, a novel anti-inflammatory and membrane-stabilizer, improves muscular dystrophy without side effects","volume":"5","author":"Heier","year":"2013","journal-title":"EMBO Mol Med"},{"issue":"3","key":"10.3233\/JND-210706_ref38","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s10571-014-0133-y","article-title":"VBP15, a novel anti-inflammatory, is effective at reducing the severity of murine experimental autoimmune encephalomyelitis","volume":"35","author":"Dillingham","year":"2015","journal-title":"Cell Mol Neurobiol"},{"issue":"SUPPL. 2","key":"10.3233\/JND-210706_ref39","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/ar1688","article-title":"The evolving clinical profile of abatacept (CTLA4-lg): A novel co-stimulatory modulator for the treatment of rheumatoid arthritis","volume":"7","author":"Ruderman","year":"2005","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"10.3233\/JND-210706_ref40","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1053\/j.seminhematol.2010.01.011","article-title":"Rituximab: Mechanism of action","volume":"47","author":"Weiner","year":"2010","journal-title":"Semin Hematol"},{"issue":"12","key":"10.3233\/JND-210706_ref41","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1016\/j.celrep.2015.05.006","article-title":"The Lipid-Modifying Enzyme SMPDL3B Negatively Regulates Innate Immunity","volume":"11","author":"Heinz","year":"2015","journal-title":"Cell Rep"},{"issue":"5","key":"10.3233\/JND-210706_ref42","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/0002-9343(81)90363-6","article-title":"Prednisone-induced leukocytosis. Influence of dosage, method and duration of administration on the degree of leukocytosis","volume":"71","author":"Shoenfeld","year":"1981","journal-title":"Am J Med"}],"container-title":["Journal of Neuromuscular Diseases"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JND-210706","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T23:49:51Z","timestamp":1777506591000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JND-210706"}},"subtitle":[],"editor":[{"given":"Jyoti","family":"Jaiswal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"Kanneboyina","family":"Nagaraju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,11,30]]},"references-count":42,"journal-issue":{"issue":"s2"},"URL":"https:\/\/doi.org\/10.3233\/jnd-210706","relation":{},"ISSN":["2214-3599","2214-3602"],"issn-type":[{"value":"2214-3599","type":"print"},{"value":"2214-3602","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,30]]}}}